FMP
Loncar Cancer Immunotherapy ETF
CNCR
NASDAQ
The index is composed of the common stock of approximately 30 pharmaceutical or biotechnology companies identified by the fund's index provider, as having a high strategic focus on the development of drugs that harness the body's own immune system to fight cancer. The adviser attempts to invest all, or substantially all, of its assets in the component securities and ADRs that make up the index. At least 80% of its total assets will be invested in the component securities of the index. The fund is non-diversified.
14.39 USD
0.44 (3.06%)
About
ceo
N/A
sector
Financial Services
industry
Asset Management
website
N/A
exchange
NASDAQ
Description
The index is composed of the common stock of approximately 30 pharmaceutical or biotechnology companies identified by the fund's index provider, as having a high strategic focus on the development of drugs that harness the body's own immune system to fight cancer. The adviser attempts to invest all, or substantially all, of its assets in the component securities and ADRs that make up the index. At least 80% of its total assets will be invested in the component securities of the index. The fund is non-diversified.
CIK
0001540305
ISIN
US26922A8264
CUSIP
26922A826
Address
N/A
Phone
NA
Country
US
Employee
N/A
IPO Date
Oct 14, 2015
Summary
ISIN
US26922A8264
Exchange
NASDAQ
Beta
0.89
Market Cap
29.57M
52-Week
9.22-17.96
Volume Avg.
37.93k
Price
14.39
Country
US
Management Assets
-
Total Holdings
-
NAV
-
NAV Currency
-
Historical Prices
We are unable to load the chart at this time.
Sector Weightings
We are unable to load the chart at this time.
Country Weightings
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest CNCR News
It looks like there's no news available.
